Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo

American Journal of Surgery

Volumn 202, Issue 6, 2011, Pages 646-653

  Cohen, Stephanie M ^a   Mukerji, Ridhwi ^a   Cai, Shuang ^b   Damjanov, Ivan ^a   Forrest, M Laird ^b   Cohen, Mark S ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Breast cancer; Combination chemotherapy; Drug delivery; Hyaluronic acid; Locoregional therapy; Nanocarriers

Indexed keywords

CISPLATIN; DOXORUBICIN; HYALURONIC ACID; NANOCARRIER;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CANCER; CANCER LOCALIZATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINE METASTASIS; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MAMMARY NEOPLASMS, EXPERIMENTAL; MAXIMUM TOLERATED DOSE; MICE; MICE, NUDE; TREATMENT OUTCOME;

EID: 82655172920     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2011.06.027     Document Type: Conference Paper

References (19)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics 2010 CA Cancer J Clin 60 2010 277 300
2. A.S. Lichter, M.E. Lippman, and D.N. Danforth Jr Mastectomy versus breast-conserving therapy in the treatment of stage I and II carcinoma of the breast: a randomized trial at the National Cancer Institute J Clin Oncol 10 1992 976 983
3. A.L. Abner, A. Recht, and T. Eberlein Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer J Clin Oncol 11 1993 44 48 (Pubitemid 23059973)
4. B.G. Haffty, D. Fischer, M. Beinfield, and C. McKhann Prognosis following local recurrence in the conservatively treated breast cancer patient Int J Radiat Oncol Biol Phys 21 1991 293 298
5. G. Bonadonna, P. Valagussa, A. Moliterni, M. Zambetti, and C. Brambilla Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up N Engl J Med 332 1995 901 906
6. M.J. Hassett, A.J. O'Malley, J.R. Pakes, J.P. Newhouse, and C.C. Earle Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer J Natl Cancer Inst 98 2006 1108 1117 (Pubitemid 44288785)
7. P.K. Singal, and N. Iliskovic Doxorubicin-induced cardiomyopathy N Engl J Med 339 1998 900 905 (Pubitemid 28446849)
8. J.T. Hartmann, C. Kollmannsberger, L. Kanz, and C. Bokemeyer Platinum organ toxicity and possible prevention in patients with testicular cancer Int J Cancer 83 1999 866 869
9. C.L. Zuur, Y.J. Simis, and R.S. Verkaik Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer Radiother Oncol 89 2008 38 43
10. J.H. Adair, M.P. Parette, E.I. Altinoglu, and M. Kester Nanoparticulate alternatives for drug delivery ACS Nano 4 2010 4967 4970
11. Y. Xie, T.R. Bagby, M.S. Cohen, and M.L. Forrest Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies Expert Opin Drug Deliv 6 2009 785 792
12. S. Cai, S. Thati, and T.R. Bagby Localized doxorubicin chemotherapy with a biopolymeric nanocarrier improves survival and reduces toxicity in xenografts of human breast cancer J Control Release 146 2010 212 218
13. S. Cai, Y. Xie, T.R. Bagby, M.S. Cohen, and M.L. Forrest Intralymphatic chemotherapy using a hyaluronan-cisplatin conjugate J Surg Res 147 2008 247 252
14. S.A. Vantyghem, A.L. Allan, and C.O. Postenka A new model for lymphatic metastasis: development of a variant of the MDA-MB-468 human breast cancer cell line that aggressively metastasizes to lymph nodes Clin Exp Metastasis 22 2005 351 361 (Pubitemid 41374291)
15. W. Feleszko, R. Zagozdzon, J. Golab, and M. Jakobisiak Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice Eur J Cancer 34 1998 406 411 (Pubitemid 28183843)
16. R. Graeser, N. Esser, H. Unger, I. Fichtner, A. Zhu, and C. Unger INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model Invest New Drugs 28 2010 14 19
17. K.D. Kiel, and A.W. Rademacker Early-stage breast cancer: arm edema after wide excision and breast irradiation Radiology 198 1996 279 283 (Pubitemid 26009708)
18. G. Liljegren, L. Holmberg Uppsala-Orebro Breast Cancer Study Group Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I Results from a randomised trial Eur J Cancer 33 1997 193 199
19. J.H. Chen, R. Ling, Q. Yao, Y. Li, T. Chen, and Z. Wang Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model Endocr Relat Cancer 12 2005 93 100 (Pubitemid 40477090)